Alzheimer's and Parkinson's charities identify new ways to reuse current drugs

Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases.
This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added.
It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service.
The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost.
Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases.
https://x.com/AlzResearchUK/status/1929856926885539966/photo/2
After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials.
Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses.
Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's.
Trial results for the Alzheimer's trial are expected to be published later this year.
Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process.
'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.'
Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs.
'Getting multiple drugs that are targeting the disease is really important to us,' she said.
'Testing different types of drugs and getting as many shots on target is important.'
She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process.
'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.'
Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'.
She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas.
'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies.
'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.'
She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS.
And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment.
'They showed for the very first time that we were able to alter the course of the disease.
'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.'
Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker.
'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Guardian

18 minutes ago

• The Guardian

Emotional MPs react to historic vote to allow assisted dying

When Kim Leadbeater walked out of the chamber of the House of Commons into parliament's central lobby, she was embraced by some campaigners who did not even know if they would be alive when the vote came. 'Overwhelmingly the sense is relief,' she said. Her close colleague, the Labour MP Lizzi Collinge was near to tears. For the Conservative Kit Malthouse, standing nearby, it was the culmination of a decade of campaigning within his own party. More than 20 of his colleagues – more than he expected – backed the bill. But even in the voting lobbies MPs were texting each other with doubts the bill would pass, so high was the tension on both sides. When the speaker read out the numbers, Keir Starmer, a longtime supporter who has tried to stay studiously neutral, allowed himself a small smile. Some opponents, many of the veteran Labour female MPs, looked deeply shaken. For Leadbeater, the vote came at a difficult time. Sunday would have been her sister Jo Cox's birthday, and last Monday was the ninth anniversary of the MP's murder. In the six months since the bill was first voted on, opposition has grown more vocal. Leadbeater feels it personally when MPs whom she hoped would support her have moved against the bill. And the attacks, particularly on social media, have become more personal. When she voted, Leadbeater said she would think about a lay preacher with terminal cancer she met in Yorkshire – Pamela – who spoke how she believed that the God of her own faith did not want suffering prolonged. 'I'm fully respectful of everybody's views when it comes to their personal faith,' Leadbeater said in her office, speaking to the Guardian in the evening before the vote. 'But the way she spoke about her religion and how that has informed her thoughts as a dying woman, I thought was very, very powerful.' Leadbeater hopes the bill will get its royal assent by October – but that will be the beginning of a four-year process to implement it, overseen by Whitehall officials. Many questions remain: how it will be funded, whether the NHS will oversee it or private providers and whether it will be free at the point of use. It will be implemented by the Department of Health and Social Care, although Wes Streeting, the health secretary, has told allies he will not seek to impede it. The day-to-day work will be handed over to the care minister Stephen Kinnock, who backed it. And there remain some assisted dying supporters in parliament who feel the bill is a missed opportunity, especially for those with neurological disorders such as Parkinson's who will not be eligible. In the public gallery on Friday, there were rows of campaigners, many of them in tears, with one clasping their hands in prayer. There have been deep bonds formed between both sides in parliament, Leadbeater was surrounded by supporters on the party's left and right, from Jake Richards to John McDonnell. In front of her were some of the bill's most active and thoughtful opponents, a group of female Labour MPs new to parliament, Jess Asato, Polly Billington and Melanie Ward. Those women each had deeply personal reasons for their opposition, such as having long careers fighting for vulnerable women and disabled people. Almost all of those who spoke – for and against – talked about some of the hardest moments of their lives, deaths of parents from pancreatic cancer, a sister with brain cancer, friends dying too young. Some supporters of the bill said they wished at times Leadbeater had taken a harder line. 'Kim has tried to be too constructive with people – you can't negotiate or work with people whose sole intent is to kill the bill. And that's what's frustrating, because whatever you give them, give them an inch and they take a mile,' one MP said. There is still deep unease among advisers in No 10 about the bill's passing and, until the 11th hour, there was a live discussion over whether Starmer would abstain on the vote – especially given the Iran situation. But, as some staffers acknowledge, it would have had echoes of Boris Johnson heading to Afghanistan to avoid a vote on Heathrow. The public, whatever the PM says about neutrality, will assume this is a Labour government endeavour. 'Perhaps there is a lesson here about not promising parliamentary time to Esther Rantzen,' one quipped. The prime minister himself had been deeply conscious of not wanting to appear to influence MPs. He had personally admonished Streeting for doing so before the last vote. But his very presence in the yes lobbies would always be a factor for some. For some MPs, there is a feeling now that the government should take ownership of the issue, as David Cameron did on equal marriage. 'Why not try and take credit for something good? A lot of people really like it,' one MP said. For the most passionate, the issue has dominated the last few months in parliament. But they are in the minority. For others, it was in the week of the final vote that they began to turn their minds to whether the agreed-upon safeguards were robust enough. The message from opponents was that it was no longer a vote on the principle – but on the detail. 'For some of us, this has been our lives for the last six months,' one senior MP said. 'For some colleagues, they just haven't thought about it at all and didn't engage back until this week. How do they really feel about being responsible for wrong or compelled deaths? That was the question put to them.' Other opponents of the bill raised concerns over the highly imperfect nature of a private member's bill, starting a bill from scratch with no heft of a Whitehall department or legislative experts. 'It's been a shocking indictment of our process generally, MPs are suddenly realising that,' said one. Leadbeater has argued to MPs that the bill has had exactly the same level of expertise and input from civil servants as any other. Significant practical changes have been made to the bill since November, including the removal of approval being needed from a high court judge. That was taken out on the demand of the Ministry of Justice, fearful of how it could gum up the courts even further. Now the process will include a panel of psychiatrist, social worker and senior lawyer. That has been met with concern among some of those professions too. The Royal College of Psychiatrists said it feared clinicians could be tied up with those decisions, rather than helping patients navigate their depression, which might enable them to recover enough to want to live longer. For some it was these concerns that were crucial to changing their votes. The Labour MP Josh Fenton-Glynn, who previously abstained, said the safeguards were not strong enough.' I don't legislate for me, I legislate for everyone including those with complex disabilities.' Dr Simon Opher, another Labour MP, said it was clear there would also be people for whom the safeguards would not be robust enough. 'What I realised in the process was that no matter how many safeguards were put in place, almost everyone who was against the bill were steadfast in their views. For many new MPs, being part of such a defining moment of social change so early in their parliamentary careers has been intense. 'It's been an incredibly emotional and at times overwhelming process to be part of, especially as a new MP,' the Lib Dem MP Tom Gordon said. The issue has dominated their postbags. But since November, most who spoke to the Guardian have noticed a concerted increase in those who were against the bill. 'It's one of the first issues in my life where I have actually seen signed petitions on paper – people who have gone door to door or passed it round a church group,' one MP said. In the final hours before the vote, opponents thought they were getting closer. A campaigner even offered to fund a private ambulance for the Alliance MP Sorcha Eastwood, an opponent of the bill, who had Covid and feared she would miss the vote – though she eventually tested negative. But though the majority has been slashed – but is still substantial enough to mean peers are unlikely block its progress. The bill will now pass to the House of Lords where it is expected to be shepherded by the Labour peer Charlie Falconer. But it is a process that is still very unpredictable. 'I thought the spreadsheet for us was hard,' one MP backing the bill said. 'That is a different level – will they turn up? Do we even know who they are?'

Daily Mirror

an hour ago

• Daily Mirror

Gastroenteritis red flags after Real Madrid ace Mbappe misses game

The Real Madrid star missed the opening Club World Cup match as he was admitted to hospital earlier this week Kylian Mbappe was hospitalised earlier this week with an 'acute case' of gastroenteritis, forcing him to miss Real Madrid's opening match in the Club World Cup on Wednesday. He has since been discharged to continue his recovery at his team's training base in America. Gastroenteritis is a very common condition usually caused by bacteria according to the NHS. It's especially common in children but can affect anyone of any age and while it usually clears up on its own, it can sometimes require hospitalisation or professional medical help. ‌ Key symptoms indicating this illness include: ‌ Sudden, watery diarrhoea Feeling sick Vomiting A mild fever Some people might also experience other issues like a loss of appetite, pain and stomach cramps or aches in their limbs and head. Symptoms will usually arise shortly after becoming infected and may last for a week or more. NHS Inform advises: 'If you experience sudden diarrhoea and vomiting, the best thing to do is stay at home until you're feeling better. There's not always a specific treatment, so you have to let the illness run its course. 'You don't usually need to get medical advice, unless your symptoms don't improve or there's a risk of a more serious problem.' Severe dehydration is a possible consequence of gastroenteritis, and this can be lethal if not treated. Symptoms of severe dehydration include not being able to pee, or only passing small amounts of urine, and persistent dizziness. ‌ If you or your child experience severe dehydration symptoms or the following issues with gastroenteritis, the NHS recommends calling 111 and getting medical help: Bloody diarrhoea Vomiting constantly, to the point where you can't keep fluids down A high fever Symptoms don't improve over a few days You have underlying conditions like kidney disease, inflammatory bowel disease or a weak immune system If you do fall ill with gastroenteritis, it's best to stay home and avoid places like work, school and hospitals as it is contagious. People can become ill due to close contact with someone with gastroenteritis, touching contaminated surfaces or objects or eating contaminated food, for example if an ill person doesn't wash their hands before cooking. The NHS noted: 'A person with gastroenteritis is most infectious from when their symptoms start until 48 hours after all their symptoms have passed, although they may also be infectious for a short time before and after this.'

Wales Online

an hour ago

• Wales Online

Chris Hoy calls for systemic change in testing for prostate cancer

Chris Hoy calls for systemic change in testing for prostate cancer The 49-year old cyclist was diagnosed with stage four prostate cancer in 2023 and was told last year that it has spread to his bones and is terminal Sir Chris Hoy has opened up about his cancer diagnosis (Image: Phil Walter, Getty Images ) Six-time Olympic champion Sir Chris Hoy has called for systemic change in the ways men get tested for prostate cancer. The 49-year old cyclist was diagnosed with stage four prostate cancer in 2023 and was told last year that it has spread to his bones and is terminal. ‌ NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier. ‌ He said: "I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger. "With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got." One option is a PSA blood test which checks the level of prostate-specific antigens in the blood, A high reading may be a sign of a prostate condition. Article continues below NHS guidance says these tests are not routinely used as they are not reliable, but men over 50 can ask GPs for one. Sir Chris's comments came after Prostate Cancer UK urged the UK Government for an overhaul of NHS guidelines to encourage GPs to proactively speak to men at high risk from 45 years old. According to the charity, around one in eight men in the UK will get prostate cancer, which occurs when cells in the prostate start to grow in an uncontrolled way and, if not detected early, risks spreading. ‌ Sir Chris added: "I believe men at highest risk, for example men with a family history like me or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. Then if there are any issues, they can get it treated it at an earlier stage. "I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility. "I've faced many challenges in my life, and going public with my prostate cancer diagnosis was certainly one of them. ‌ "I've been incredibly lucky to have so much support from my family, friends and the general public. The kindness has lifted me up and given me a sense of purpose, and I'm committed to taking that forward and using my platform to raise awareness of the most common cancer in men and help more men at risk to come forward and get tested." The Scottish cyclist has launched his own charity cycling challenge, Tour de 4, with the aim of changing perceptions around stage four cancer. The challenge will take place on September 7 in Glasgow with a final registration phase open for riders to sign up. ‌ Speaking about Sir Chris, Laura Kerby, chief executive at Prostate Cancer UK, said: "His bravery and tireless work to raise awareness has already made a huge impact. "In just a few months after Sir Chris went public with his diagnosis last year, over 286,000 people used our online risk checker to learn more about the disease, find out their own risk and learn what they can choose to do about it. "His bravery has inspired so many men to take action, and he has undoubtedly saved lives. Article continues below "One in eight men will get prostate cancer. The earlier it's found, the easier it is to treat - but there's currently no screening programme in the UK. So if, like Sir Chris, you have a family history of the disease, or if you're black, we strongly encourage you to speak to your GP about testing from the age of 45. "We don't think it's right that the responsibility is all on men's shoulders, so we're calling on the Health Secretary to overhaul outdated NHS guidelines so that GPs are empowered to actually start conversations with these men at highest risk." The Department for Health and Social Care has been contacted for comment.